Etoposide, an effective agent for acute lymphoblastic leukemia (ALL), can cause secondary acute myeloid leukemia (AML) in a subset of patients. Our objectives were to determine whether patients who develop secondary AML displayed altered etoposide pharmacokinetics or other pharmacologic characteristics compared to identically treated patients who did not develop AML. Children with newly diagnosed ALL were treated according to a protocol which included etoposide 300 mg/m 2 given three times over 8 days during remission induction and once every 2-4 weeks during 120 weeks of continuation therapy. Characteristic 11q23 rearrangements were documented in seven of the eight patients with AML. Etoposide clearance, time that etoposide concentrations exceeded 10 M, etoposide or etoposide catechol area-under-the-plasma-concentration vs time curve (AUC), serum albumin, and average methotrexate concentration did not differ significantly between the two groups; thiopurine methyltransferase (TPMT) activity tended to be lower in the eight children who did vs the 23 matched control children who did not develop AML (P = 0.16). Further regression analyses likewise indicated that lower TPMT activity tended to be associated with shorter onset of secondary AML (P = 0.11); it also tended to be lower among the eight index cases compared to the entire unmatched cohort of 105 identically treated children with ALL (P = 0.10). We observed no statistically significant differences in etoposide disposition and antimetabolite pharmacology between patients who did and did not develop secondary AML.
Introduction
The epipodophyllotoxins, etoposide and teniposide, are a class of antineoplastics for which pharmacodynamic relationships have been established: ie plasma concentration of parent drug correlates with both anticancer effect [1] [2] [3] and acute toxicity (eg myelosuppression).
2,4-8 However, defining the optimal dosages and schedules of the epipodophyllotoxins has proven challenging, in part due to a 10-fold interpatient variability in systemic clearance [9] [10] [11] [12] [13] [14] and because we do not understand the risk factors for their most devastating delayed toxicity: the development of secondary acute myeloid leukemia (AML) in as many as 10-20% of adult and pediatric patients. [15] [16] [17] [18] [19] The epipodophyllotoxins are often incorporated into treatment regimens for the most common childhood malignancy, acute lymphoblastic leukemia (ALL). 20 However, some of the same epipodophyllotoxin-including dosage regimens that produce excellent antileukemic effect for ALL have unfortunately been associated with an increased risk of secondary AML. 18, 21 Thus, it is important to determine why some ALL patients develop AML as a consequence of therapy that is curative in Ͼ70% of children so treated. Although several treatment regimen-related factors (eg schedule, 18 concurrent use of asparaginase 22 or cumulative dose 23 ) have been hypothesized to be associated with an increased risk of epipodophyllotoxin-induced AML, there are no known patient-specific risk factors by which one can identify patients at higher risk for its development. Furthermore, no studies have evaluated whether interindividual differences in the pharmacokinetics of etoposide, or of its reactive Odemethylated metabolities, or both, contribute to the risk for development of secondary AML.
In our recently completed front-line protocol for treatment of childhood ALL, SJCRH protocol Total XIII, eight children developed secondary AML. Children on this protocol had assessments of etoposide disposition and antimetabolite pharmacology performed at times specified by the treatment protocol, affording us the opportunity to compare these assessments in children who went on to develop secondary AML vs a matched cohort of identically treated children who did not develop secondary AML.
Patients and methods

Patients
A total of 154 children with newly diagnosed ALL were enrolled (after obtaining informed consent from the parent or guardian) on our front-line therapeutic protocol SJCRH Total XIIIHR (Table 1) . 24, 25 With a minimum of 38 months of followup from diagnosis of ALL for all patients, eight children developed secondary AML, four of whom have been described previously. 22, 25 In order to control for as many factors as possible that could affect drug disposition and to ensure equivalent drug treatment, patients who were treated on the same protocol and had not developed secondary AML were matched to secondary AML cases using the following criteria: same immunophenotype category for the original ALL (B progenitor vs T cell), identical number of asparaginase doses delivered during induction therapy, same sex, same number of days (±2 days) required to deliver remission induction therapy, and identical pre-induction methotrexate therapy (ie low-dose vs high-dose) 26 except in one case, in which the AML case was an unusual patient who received no window therapy. At least two and up to four matches were found for each AML case. If there were more than two matches for the discrete variables, proximity of age (younger or older than 9 years of age and usually within 2 years of each other) was used as the criterion for the selection of the matches. Thus, except for the one child who received no pre-induction methotrexate, all cases and controls received identical chemotherapy. All controls have been followed for at least 38 months (as of October 1997), which is longer than the longest latency period between ALL and AML diagnosis in the indexed cases. In addition to the eight children who developed secondary AML, a total of 105 children who did not develop secondary AML received all nine doses of asparaginase during remission induction, completed remission induction within 10 days of the scheduled time period, and had erythrocyte thiopurine methyltransferase (TPMT) activity measured at day 44 of remission induction; these 105 patients constituted the entire cohort from which the matched controls were selected and served as an additional control group for comparison of TPMT activity (see below).
Samples
On day 29 of remission induction therapy, serum albumin was measured, and blood in heparinized tubes was obtained preand at 1, 1.5, 2, 6 and 24 h following etoposide 300 mg/m 2 i.v. over 2 h for etoposide measurements. This was the third of a planned total of 48 identical doses of etoposide that were given over 2.5 years of ALL therapy (Table 1) . 22 The plasma was stored at −70°C until the time of analysis. On day 44 of remission induction therapy, red blood cell lysates from heparinized blood samples were used to measure TPMT activity, just prior to the first consolidation doses of 6-mercaptopurine. Plasma for methotrexate concentration was measured 44 h following the start of each course of high-dose MTX.
Diagnosis of AML
Children had bone marrow aspirates performed at diagnosis of ALL, on day 43 of remission induction therapy, and at weeks 15, 29, 53, 69, 81, 94 and 120, or at any time when relapse was suspected. When the diagnosis of AML was suspected, the samples were analyzed by cytogenetics and by Southern blot for MLL rearrangements 27 or by reverse transcriptase polymerase chain reaction for common translocation transcripts involving MLL (eg t(9;11) and t (11;19) ).
Pharmacologic studies
Etoposide and its catechol were measured in duplicate using minor modifications of a previously described HPLC assay 28 with electrochemical detection. Using 200 l of plasma per replicate, the limits of detection for etoposide and etoposide catechol in plasma were approximately 0.001 M and 0.0017 M, respectively. A first-order two-compartment structural pharmacokinetic model was used to simultaneously fit the parent drug and etoposide catechol data (Figure 1 ), using a Bayesian estimation algorithm implemented in Adapt II. 29 The pharmacokinetic parameters and coefficients of variation used in the prior mean vector and the initial estimates for etoposide (V c , K e-Total , K cp , K pc ) were identical to those we have previously reported; 28 in addition, we assumed that the intercompartmental distribution rate constants and central volume of distribution for the etoposide catechol were identical to those for etoposide (preliminary experiments indicate comparable plasma protein binding for both etoposide catechol and parent drug), and we used initial estimates and prior means for the elimination rate constant for the etoposide catechol (Ke cat ) of 0.002 h −1 and rate constant for conversion of etoposide to etoposide catechol (K vpPcat ) of 1.25 h −1 , incorporating extremely large coefficients of variation, since no prior data were available. In addition to the primary etoposide pharmacokinetic parameters, we also estimated: AUC for both etoposide catechol and parent drug from 0 to 24 h using standard noncompartmental techniques with simulated concentrations every 10 min, etoposide clearance as Vc·Ke total or as dose/AUC, and time that plasma concentrations exceeded a mutagenic concentration 30 of 10 M (t Ͼ 10 M). Erythrocyte TPMT activity was measured as previously described. 31 Plasma methotrexate concentrations were measured using a fluorescence polarization immunoassay (TDx, Abbott Laboratories, Abbott Park, IL, USA); the average of the concentrations measured 44 h (at which time leucovorin rescue began) following the first five courses of MTX (over the first 6 months of therapy) was used in the analyses.
Statistics
A matched case-control study design was used to screen for possible pharmacologic factors that differed between children who did and did not develop secondary AML. The values of parameters from the matched controls were compared to the observed parameter values for the patients with secondary AML using an exact Wilcoxon test 32, 33 stratified for matching. An exact conditional logistic regression analysis, 34 stratified for matching, was used to assess whether age, etoposide pharmacologic parameters, albumin, TPMT, or average 44 h MTX concentration were predictive for the development of secondary AML. Among those with AML, correlations among pharmacologic parameters and time to onset of AML were assessed using Spearman's rank tests. A Cox proportional hazards regression model was used in a forward stepwise fashion to assess pharmacologic factors for possible correlation with time to onset of secondary AML. Based on results of the casecontrol analysis, one of the pharmacologic variables (ie TPMT activity) was compared in the entire cohort from which the controls were selected and the eight AML cases, using a Wilcoxon test.
Results
Eight patients developed secondary AML at 12-30 months (median 24 months) from diagnosis of ALL; the myeloid blasts were characterized by 11q23 translocations in seven cases. Characteristics of the eight patients who developed secondary AML and those of the control patients are summarized in Table 2 . The only two discrete variables that were not matched between the AML group and the controls were race and pre-induction methotrexate therapy; however, these two variables are unlikely to affect the pharmacologic parameters of interest, because there was no significant difference in etoposide clearance, AUC, t Ͼ 10 M, etoposide catechol AUC, fraction unbound, albumin, erythrocyte TPMT activity, and average MTX concentrations in the low-dose vs the high-dose group or in blacks vs whites (data not shown). There was no attempt to match initial leukocyte count in the two groups, but they did not differ in this respect (P = 0.70).
Pharmacologic parameters (Table 3) were compared between the eight patients with secondary AML and their matched controls. TPMT activity tended to be lower (P = 0.16) in the patients who developed secondary AML. A logistic regression analysis, stratified by the matching chosen for the controls, revealed no statistically significant predictors of secondary AML.
Because the pharmacologic variables evaluated were all assessed early in ALL treatment (less than 6 months from a None of the patients were Hispanic. With the exception of one case with AML having two white and two black control matches, races of index cases and their controls were identical. diagnosis), we explored whether the time of onset of AML was related to TPMT activity or to other pharmacologic variables, hypothesizing that early onset of AML might be more likely related to measured pharmacologic variables than later onset. Figure 2 depicts the relationship of onset of AML vs various pharmacologic variables. Whether the analysis of the time to onset of AML was stratified using the eight strata based on matching controls for every AML case, or those strata were ignored and replaced by a post hoc stratification based on age, race, and immunophenotype of ALL, no factors were significantly related to shorter onset of development of AML, with P values of 0.11 and 0.065, respectively, for lower TPMT activity, and P = 0.17 and P = 0.15, respectively, for higher average MTX concentrations. Although etoposide pharmacokinetic data were not evaluated in all patients enrolled on the protocol, erythrocyte TPMT activity was assessed in most patients at day 44 of remission induction therapy. In order to further investigate whether TPMT activity is related to the risk of secondary AML using all data available, we compared this parameter in the eight children who developed secondary AML and in the 105 identically treated children for whom erythrocyte TPMT activity had been assessed. Median TPMT activity was 14.2 in the secondary AML patients vs 17 .0 units/ml packed red blood cells in the controls (P = 0.10 by Wilcoxon test).
Discussion
This is the first report of pharmacologic characteristics of patients who have developed epipodophyllotoxin-related AML. Here, we were able to compare etoposide and its metabolite pharmacokinetics, methotrexate plasma concentrations, and thiopurine methyltransferase activity in a group of children who developed AML to an identically treated control group of children who did not develop AML. Although we observed no statistically significant differences at the traditional 0.05 level in these pharmacologic parameters between the two groups of patients, there was a trend for lower thiopurine methyltransferase activity in the children who went on to develop AML. This trend was also observed when TPMT was compared in the eight patients who developed AML and the larger unselected control group of 105 children who did not develop AML. Because our assessments of etoposide and antimetabolite pharmacology were made early on in the course of these children's ALL therapy, we reasoned that these pharmacologic assessments might be most informative for prediction of early-onset secondary AML, assuming that early onset corresponds with the early occurrence of an etoposide-related leukemogenic effect. There was, in fact, a trend indicating lower thiopurine methyltransferase activity associated with shorter onset of AML; in analyses with onset to AML as the dependent variable, there was also a suggestion that MTX plasma concentration tended to be higher in those with shorter onset AML.
Most reports of very high frequencies of epipodophyllotoxin-associated AML have involved clinical protocols in which epipodophyllotoxins immediately followed fairly prolonged courses of antimetabolite therapy (ie daily 6-mercaptopurine and weekly methotrexate). 15, 17, 18 Antimetabolite therapy and folate deficiency have been shown to contribute to mutagenesis and carcinogenesis. 35, 36 In addition, complex interactions of mercaptopurine and methotrexate, which might affect S-adenosyl methionine concentrations and the state of DNA methylation, 37 could predispose to nonhomologous recombination following etoposide. One of the most important determinants of toxicity from exposure to active thioguanine nucleotides formed following 6-mercaptopurine therapy is the activity of erythrocyte thiopurine methyltransferase. 38 These considerations were the underpinnings for our assessments of TPMT and methotrexate plasma concentrations as possible risk factors for etoposide-induced AML. Thiopurine methyltransferase activity tended to be lower in patients who developed AML vs those who did not in a univariate analysis (P = 0.16 compared to matched controls and P = 0.10 compared to all available controls), in a conditional logistic regression analysis (P = 0.19), and in a multivariate Cox proportional hazards model with time to onset of AML as the dependent variable (P = 0.11). The fact that P values of less than the traditional 0.05 were not observed is not surprising, given the small number of secondary AML cases. Lower TPMT activity would result in greater exposure to active thiopurine nucleotide metabolities, and would be consistent with prior antimetabolite therapy enhancing etoposide's leukemogenic effects through a number of possible mechanisms.
Our choice of pharmacologic factors for study warrants some comment. The secondary AML associated with epipodophyllotoxins, characterized by short onset, MLL gene rearrangements, and monoblastic phenotype, 19 seems to be related to the ability of these agents to interfere with the normal activity of topoisomerase II. Most cases have been reported following administration of etoposide and teniposide, both of which interact very potently with topoisomerase II.
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Figure 2
Plots of onset of secondary AML vs various pharmacologic parameters; lines are simply the least squares best fit. The Spearman rank correlation coefficients (r s ) and associated P values are as follows: TPMT (thiopurine methyltransferase) activity, r s = 0.73, P = 0.04; etoposide clearance, r s = 0.85, P = 0.007; time that plasma etoposide concentrations exceeded 10 M, r s = −0.85, P = 0.007; serum albumin, r s = 0.76, P = 0.028; percent unbound etoposide in plasma, r s = −0.18, P = 0.67; average methotrexate 44 h plasma concentration, r s = 0.38, P = 0.35.
Similarly characterized secondary AML cases have been reported less frequently following the use of less potent topoisomerase II-active agents (eg doxorubicin). 16 Moreover, the balanced translocations 27 and concentration-dependent recombinogenic effects 30 of etoposide are plausible compensatory changes in response to inhibition of topoisomerase II's religation of double-stranded DNA breaks. Therefore, it is possible that secondary AML might be more likely in patients who achieve high systemic concentrations of etoposide, or in those whose plasma concentrations of etoposide remained for a longer time above a concentration with high recombinogenic effects in vitro, 10 M. 30 Although increased etoposide exposure was correlated with onset of AML among those who developed AML (Figure 2) , the fact that these parameters did not tend to be different in children who did vs those who did not develop AML suggests that additional factors not directly related to etoposide exposure may be involved in protecting patients from development of etoposide-induced AML.
There are several caveats that must be acknowledged in interpreting these findings. One consideration is that etoposide pharmacokinetics were measured on only one occasion, with the third dose of etoposide, at the end of remission induction therapy. This is problematic in that it is not known to what degree this measurement of etoposide pharmacokinetics would be correlated with subsequent measurements throughout the next 2.5 years of therapy. We do know that, on the whole, the systemic clearance of a model substrate for hepatic cytochrome P450 metabolism (antipyrine) measured at the end of remission induction therapy does not change significantly throughout the course of 2.5 years of continuation therapy (unpublished data), and that etoposide is metabolized by one of the same enzymes (CYP3A4) 40 metabolizing antipyrine. 41 However, there are individual patients who occasionally exhibit changes in etoposide clearance, and whether such changes occur more or less frequently among children who develop AML than among those who do not cannot presently be known without making measurements with every single course of etoposide. Nonetheless, there are data to indicate that intrapatient variability in etoposide pharmacokinetics 4 and in CYP3A4 42 is less than interpatient variability, suggesting that the data here from a single time-point may have some relevance to the total exposure to etoposide for any given patient. Another major caveat in interpreting our data is that, because of the relatively small number of secondary AML cases (eight), we have very limited power to discern differences in pharmacologic parameters between children who do and do not develop secondary AML. Because of our limited power, we emphasize that the finding that TPMT activity tended to be lower among those with AML may be important and worthy of further study, while the lack of significant associations with other pharmacologic parameters must not be interpreted as definitive.
A remarkable feature of the etoposide pharmacokinetic data described here is the very high systemic etoposide clearance in the entire group of patients, with a median of 43 ml/min/m 2 . This clearance is higher than that reported in seven previous studies in children 1, 6, 9, 12, 28 and 14 previous studies in adults. 1, 2, 7, 11, 13 One possible explanation for the very high clearance we observed is that the previous 4 week course of prednisone may have induced CYP3A4 43 metabolism of etoposide, 40 a finding consistent with our previous observations of enhanced P450 metabolism following remission induction. 44 In summary, although our data should be interpreted with caution due to their retrospective nature and the small number of patients, they represent the only pharmacokinetic data available in identically treated patients who did and did not go on to develop epipodophyllotoxin-associated AML, and may provide insights into variables that deserve further study. Our results suggest that low thiopurine methyltransferase activity may increase the risk of epipodophyllotoxinassociated AML among ALL patients. Ongoing studies in preclinical models in our laboratory are aimed at defining less recombinogenic etoposide-containing regimens without compromising their efficacy.
